Associated Papers
Meta-GWAS of PCSK9 levels detects two novel loci at APOB and TM6SF2.
Pott J et al.
Human Molecular Genetics, 2022
PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis.
Guo Q et al.
Frontiers in Genetics, 2020
Loss-of-Function PCSK9 Mutations Are Not Associated With Alzheimer Disease.
Paquette M et al.
Journal of Geriatric Psychiatry and Neurology, 2018
The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.
Seidah NG et al.
Pharmacological Reviews, 2017
PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.
Marais AD et al.
Pharmacology & Therapeutics, 2015
Regional distribution and metabolic effect of PCSK9 insLEU and R46L gene mutations and apoE genotype.
Awan Z et al.
The Canadian Journal of Cardiology, 2013
Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture.
Mayne J et al.
Clinical Chemistry, 2011
Molecular analysis and intestinal expression of SAR1 genes and proteins in Anderson's disease (Chylomicron retention disease).
Georges A et al.
Orphanet Journal of Rare Diseases, 2011
The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene.
Abifadel M et al.
Human Mutation, 2009
Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.
Abifadel M et al.
Human Mutation, 2009
A PCSK9 variant and familial combined hyperlipidaemia.
Abifadel M et al.
Journal of Medical Genetics, 2008
Genetic heterogeneity of autosomal dominant hypercholesterolemia.
Varret M et al.
Clinical Genetics, 2008
[After the LDL receptor and apolipoprotein B, autosomal dominant hypercholesterolemia reveals its third protagonist: PCSK9].
Abifadel M et al.
Annales D'endocrinologie, 2007
Unravelling the functional significance of PCSK9.
Lambert G
Current Opinion in Lipidology, 2007
Proprotein convertase subtilisin/kexin type 9, its variants and regulation of low-density lipoprotein cholesterol.
Wierzbicki AS
Current Opinion in Lipidology, 2007
The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population.
Yue P et al.
Human Mutation, 2006
Select a paper to view details